For Healthcare Bankers: Rx v OTC

For Healthcare bankers, I was looking through comparable companies and noticed something a bit strange - it seems that generic OTC drug manufacturers trade at a higher multiple than generic Rx drug manufacturers. I know that there is tough competition in the generics Rx space, but why not the same discount to OTC? Is there something about OTC that protects them from that steep competition? Thank you!

7 Comments
 

Not a pharma expert, but here's a few guesses as to why this is:

  • OTC products are consumer-facing and aren't facing the same pricing pressure as the Rx side. Differentiation can occur through marketing, packaging, etc.

  • Rx products go through prescribers and generics are not promoted and not differentiated, so it becomes a pricing competition

 

Thank you so much for the reply. I agree that OTC at point of sale are able to differentiate from one another, but do you think that holds for the manufacturers that sell to these retailers - I am referring more to the guys that exclusively manufacture OTC drugs for the wallgreens, CVS of the world, and do little to no e-commerce themselves. Do you have any opinions on that space?

 
Most Helpful

Without getting too technical here, it comes down to product access. Anything you can get OTC is essentially manufactured the same way the Rx equivalent is. The FDA requires drug monographs to prove that the drug in question is the same as the drug it's based on. From a product standpoint, the only difference between the prouct is the amount of active ingredient available in the OTC version vs the Rx version. From a consumer standpoint, the big issue is whether the drug is safe for self-administration, as minimal addictive potential, and it can be shown that the consumer can follow the label. From there, once a drug is OTC, it's all the standard differentiation issues. So why are they trading at higher multiples? They are dealing in drugs that don't have the same strict restrictions as their Rx counterparts have..

In terms of brands that are white labeled, the cost of a pill is dirt cheap. I won't be surprised if the OTC manufacturers produce extra pills and white label them for resale through places like CVS, and WGA. In order to make it viable to exclusively retail a white OTC, you need to be able to sell a ton of pills at wholesale. What you need to understand is that the cst producing these pills works out to something like a penny a pill. Running a manufacturing plant that produces small molecule pills is extremely capital intensive and has significant regulatory oversight. If you're making the API (active pharmaceutical ingredient) for a small molecule, the cost of production is relatively cheap, so increasing the volume and white labeling becomes a cost effective way to increase revenue.

 

Thank you so much for your response! This is so incredibly helpful. Quickly, when you say "the same strict restrictions as their Rx counterparts" what are those restrictions. Additionally, with respect to manufactures and the CVSs of the world, how sticky are the relationships - and on a related note are the revenue models typically a contractual agreement for CVS to buy 100k pills over the next 2 years from a manufacturer or what to they look like, if you have any insight. Thank you again!

 

IF a drug is OTC, you can, in theory, buy as much of it as you want. For an Rx, drugs are subject to tons of restrictions, from reporting requirements with Narcotics, to quantity limits with certain product types, to how often Rxs can be refilled. Plus, there's the fact that an Rx is a response to medical treatment, which means there's a higher standard of care involved over self-diagnosis and administration. If you have a headache, take a tylenol. If you have blood clotting issues, you talk to your doctor about getting a prescription for Eliquis and accept that it comes with a shit ton of patient monitoring and testing requirements. All of these added restrictions directly impact a drug manufacturer's ability to get a product out to consumers. So even though you have a 30 day script for Warfarin with a 2x refill built in, there are restrictions in place as to when you can get the prescription.

As an added point, you also have to look who generics are competing with. Using Warfarin as an example, it's the generic that's competing againt Eliquis and Xarelto. Warfarin has half a dozen manufacturers. Not every CVS or Walgreens is going to stock the same generic medications. By the way, if you take generics and raelize that one particular pill works better or worse than the other, it may not be a bad idea to ask if your pharmacy has that particular generic manufacturer in stock.

To oyur question on what the relationship for generic OTC is for a company like CVS is, I honestly don't know. I'd assume it's a standard wholesale model. Now, if you were talking on the Rx side, that's a far more interesting discussion.

 

Quo ut sed sequi eveniet. Maiores facilis corrupti repellat quibusdam aut. Perspiciatis consequatur repellat doloribus. Ipsam sapiente vel repellendus. Corporis nisi aut iusto ut dolores repudiandae.

Veniam harum est alias dolorem. Deleniti porro et atque nam itaque vero. Adipisci dolor consequuntur voluptatem. Totam facilis quia quis aut provident error occaecati.

Quisquam qui quaerat qui et saepe nemo at. Ut minus maxime minima laboriosam. Adipisci beatae aut enim excepturi. Mollitia ullam amet voluptas veritatis. Rerum fuga qui dignissimos et error voluptas. Placeat pariatur sed aperiam consequatur nihil provident atque. Ut et sit consequatur quidem sed saepe.

 

Eius quia quidem vel ea recusandae explicabo. Dolore soluta enim quasi minima voluptatem esse. Voluptatum rerum et quibusdam sunt sed rem similique. Ullam similique quia numquam et rerum pariatur.

Rerum culpa ducimus facere nulla et et. Recusandae eius mollitia ipsum voluptatem dolores rerum maxime. Occaecati autem reprehenderit eligendi ea non error ut earum.

[Comment removed by mod team]

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.9%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 03 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 07 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (51) $260
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (26) $182
  • Intern/Summer Associate (15) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”